0 NASDAQ Companies - June 27, 2019Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with EculizumabRead More
0 NYSE Companies - June 27, 2019Leading Women Entrepreneurs Honors FTI Consulting’s Dawn HallRead More
0 NASDAQ Companies - June 27, 2019Primoris Services Corporation Announces Industrial Awards Valued Over $69 MillionRead More
0 NASDAQ Companies - June 27, 2019Kitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck CancersRead More
0 NASDAQ Companies - June 27, 2019OpGen’s Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted TherapyRead More
0 NASDAQ Companies - June 27, 2019Customers in Denver and Providence are the next to get Verizon 5G Ultra Wideband serviceRead More
0 TSX News - June 27, 2019ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed AntibodiesRead More
